Global  

Gilead says remdesivir cuts death risk

Video Credit: Reuters Studio - Duration: 01:04s - Published
Gilead says remdesivir cuts death risk

Gilead says remdesivir cuts death risk

Gilead Sciences said Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients.

Fred Katayama reports.

0
shares
ShareTweetSavePostSend
 

💡 One News Page Knowledge: Other News Mentions

Gilead Sciences American pharmaceutical company

State attorneys general: Use federal law to lower cost, increase supply of COVID-19 drug remdesivir

California, Louisiana and other attorneys general say Gilead Sciences' antiviral should be licensed to others to ease potential shortages, lower price

USATODAY.com
Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62% [Video]

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62%

The antiviral drug Remdesivir has proven to be effective in the treatment of COVID-19. According to UPI, the drug can lower the risk of death in COVID-19 patients by 62%. U.S. drugmaker Gilead Sciences reported the new data on Friday. Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 clinical trial. There have been over 3.4 million confirmed cases of coronavirus in the U.S., with a death toll of 138,247 people.

Credit: Wochit News    Duration: 00:32Published
Gilead sparks Wall Street rally [Video]

Gilead sparks Wall Street rally

U.S. stocks rose Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:20Published
Gilead's remdesivir gets conditional EU clearance [Video]

Gilead's remdesivir gets conditional EU clearance

The European Commission said Friday it had given conditional approval for the use of antiviral drug remdesivir in severe COVID-19 patients. As Fred Katayama reports, that makes it the region's first authorized therapy to treat the virus.

Credit: Reuters Studio    Duration: 00:59Published

Fred Katayama journalist

Investing beyond stay-at-home stocks [Video]

Investing beyond stay-at-home stocks

John Hancock Global Thematic Opportunities Fund's Gert Van Der Geer identifies long-term themes that haven't played out in the market yet. He tells Reuters' Fred Katayama medical technology companies such as Boston Scientific and Edwards will bounce back once people undergo elective surgeries that they put off amid the lockdown.

Credit: Reuters Studio    Duration: 04:17Published
Teladoc buys Livongo in $18.5 billion deal [Video]

Teladoc buys Livongo in $18.5 billion deal

Teladoc Health has agreed to buy chronic care provider Livongo Health in a deal valuing the company at $18.5 billion that bets on a boom in online care and consultations spurred by the coronavirus crisis. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:13Published
Stocks rise, Disney surges after hours [Video]

Stocks rise, Disney surges after hours

Wall Street ended higher after a choppy session on Tuesday, but they were capped by declines in AIG and Microsoft. As Fred Katayama reports, Disney shares shot higher after its adjusted profit handily beat expectations.

Credit: Reuters Studio    Duration: 01:28Published
Pandemic hammers Ralph Lauren's revenue [Video]

Pandemic hammers Ralph Lauren's revenue

Ralph Lauren said Tuesday its quarterly revenue plunged by nearly $1 billion, as it struggled with coronavirus-led store closures and a global slowdown in demand for luxury goods. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:09Published
Nasdaq surges on megacap earnings [Video]

Nasdaq surges on megacap earnings

The Nasdaq jumped more than 1% on Friday, powered by strong earnings from some of the largest U.S. companies, but the Dow and S&P finished with smaller gains as uncertainty about the government's next round of coronavirus aid kept economic worries on the radar. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:27Published

You Might Like

Related news from verified sources

Gilead: Remdesivir Cut Risk of Death in COVID-19 Patients, More Studies Needed

Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral...
Newsmax - Published Also reported by •Motley FoolFOXNews.com



Tweets about this